Measurement of glucose levels in the newborn (original) (raw)
Related papers
Evaluation of two glucose meters and interference corrections for screening neonatal hypoglycemia
Pediatrics international : official journal of the Japan Pediatric Society, 2014
Many neonatal intensive care and maternal units still use self-monitoring of blood glucose (SMBG) devices as a tool to aid diagnosis despite the introduction of point-of-care testing (POCT) devices, which are known to have higher accuracy. We evaluated the performance of two glucose meters, the StatStrip (Nova Biomedical), a POCT device, and the Medisafe Mini (Terumo), a SMBG device, to detect hypoglycemia in neonates. In addition, we evaluated the interference of hematocrit, acetaminophen and ascorbic acid. Whole blood samples were drawn from neonates who were at risk of hypoglycemia and analyzed with the StatStrip and Medisafe Mini. The results were further confirmed by blood gas analyzers ABL825 and BM6050. To evaluate the interference of hematocrit, acetaminophen and ascorbic acid, concentrated solutions of glucose and interfering substances were gravimetrically prepared and analyzed. Among the 222 blood samples analyzed, results from the StatStrip were more closely aligned to t...
Turkish Archives of Pediatrics
What is already known on this topic? • A continuous glucose monitoring system using factory-calibrated sensors was recently approved for diabetes management in persons aged ≥18 years. Although it has reasonable accuracy and usefulness in children with type 1 diabetes, there are no reports on its safety and feasibility in newborn infants. What this study adds on this topic? • Values from this continuous glucose monitoring system were compared with blood glucose concentrations in term and near-term infants at risk of hypoglycemia after delivery. This system was a safe and feasible method for glucose control but had a tendency to overestimate the blood glucose concentrations. We should use this system cautiously for neonates at risk of hypoglycemia, especially within 3 hours after sensor placement.
2014
Hypoglycemia is considered as a serious risk factor in neonates. In the majority of cases, it occurs with no clinical symptoms. Accordingly, early diagnosis is extremely imperative, which can also lead to less morbidity and mortality. The aim of this study was to assess the importance of screening blood glucose using glucometer (known as a quick and cost-effective diagnostic test) in comparison with laboratory method. A total of 219 neonates at risk of hypoglycemia were included in this study. Blood glucose was measured by glucometer and laboratory. In addition glucose level of capillary blood was measured by glucometer at the same time. Sensitivity and specificity of capillary blood glucose measurement by glucometer were 83.5%, 97.5% respectively (ppv=80%), (npv=98%). Capillary blood glucose measured by glucometer has an acceptable sensitivity and specificity in measurement of neonatal blood glucose. Therefore measurement by glucometer is recommended as a proper diagnostic test.
Journal of clinical and diagnostic research : JCDR, 2014
Neonatal hypoglycemia is the most common carbohydrate metabolic disturbance seen in case of neonates and especially in preterm neonates. Accurate and rapid determination of hypoglycemia and its prompt treatment is of utmost importance to decrease morbidity and mortality of neonates. To estimate blood glucose in neonates and test the efficacy of HemoCue Glucose 201+ analyser and B Braun Glucometer by comparing with centralised laboratory testing. To compare the blood glucose in capillary and venous blood samples of neonates. Hospital setting; Comparative Study Materials and Methods: After obtaining informed consent, all neonates admitted to Neonatal Intensive Care Unit (NICU) were screened for blood sugar. Capillary and venous blood glucose was estimated employing HemoCue Glucose 201+ analyser and B Braun Glucometer. Simultaneously, the same venous sample was collected in fluoride tube and sent to central clinical biochemistry laboratory for glucose estimation. When anaemia or polycy...
Neonatal Blood Glucose Assessment (Glucometer Vs Serum
ALAZHAR UNIVERSITY, 2022
Background: One of the greatest prevalent metabolic problems in newborns is hypoglycemia. Neonatal hypoglycemia may be both symptomatic and asymptomatic. Hypoglycemia has been linked to cognitive impairment and neuromotor developmental delay. Aim of the study: The goal of the research was to discover the mean difference and correlation between capillary bedside glucose estimation by using glucometer in comparison venous sampling by using laboratory method. Patients and Methods: This cross-sectional comparative prospective research was undertaken on 200 newborns that were admitted to special care baby unit at Al-Wahda teaching Hospital-Derna, Libya from March 2018 till March 2019. Results: Agreement between blood sugar and glucometer blood sugar. Showing a significant agreement between venous blood sugar and glucometer blood sugar. Significant positive correlation between venous blood sugar and glucometer blood sugar. Conclusion: Given the significance of blood sugar levels in the identification of hypoglycemia in the early hours of life, glucometer readings must be reliable. Furthermore, these glucose meters need skin breaking, which causes discomfort and the risk of infection. However, there are presently no painless and non-invasive procedures for precisely determining glucose levels in newborns. There is a demand for the creation of such gadgets for valid reasons.
Journal for Specialists in Pediatric Nursing, 2002
issues and purpose.Rapid identification and treatment of glucose abnormalities is crucial in the prevention of potentially devastating neurological injury in neonates. Choice of a point-of-care glucose testing system must consider accuracy, clinical advantages, and data management capabilities.conclusions.The benefits and limitations of point-of-care testing must be weighed against the time delay of central laboratory testing.practice implications.Considerations in selecting a point-of-care blood glucose monitoring system include accuracy, precision, versatility, and the potential for cross infection and blood loss. When a system is selected, studies must be done to identify potential sources of error and confirm the utility and accuracy of the system in the identified population.
Italian Journal of Pediatrics, 2018
Background: Continuous glucose monitoring using subcutaneous sensors is useful in the management of glucose control in neonatal intensive care. We evaluated feasibility and reliability of a continuous glucose monitoring system in a population of very low birth weight neonates needing parenteral nutrition. Moreover, we presented percentiles of glycemia of the studied population. Methods: Very low birth weight neonates were enrolled within 24 h from birth. An ENLITE sensor connected to a continuous glucose monitoring system was inserted and maintained for at least 72 h. Data obtained with the continuous glucose monitoring system and with a glucometer were compared. Calibration was performed every 12 h. Results: Twenty-three patients (9 males) were included. Median gestational age was 28 weeks (range 23-30) and median birth weight was 860 g (range 500-1092). A total of 299 paired glucose values were obtained. Modified Clarke Error Grid criteria for clinical significance were met. 74 and 33 episodes of hypoglycemia and hyperglycemia were detected, respectively. 31,329 values of glycemia were analyzed and the percentiles calculated. Conclusions: This continuous glucose monitoring system is safe and accurate. It allows increasing the detection of hypo-and hyper-glycaemia episodes and it could be routinely used in the management of glucose infusion in very low birth weight neonates under total parenteral nutrition.
Archives of Disease in Childhood - Fetal and Neonatal Edition, 2018
In the very low birthweight (VLBW) infant population, high glucose concentrations have been associated with increased mortality, brain injury, retinopathy of prematurity and worse neurodevelopmental outcomes. However, trials to prevent or treat hyperglycaemia in this population with continuous insulin infusions or a combination of insulin and/or reductions in the glucose infusion rate have been complicated by more frequent episodes of low glucose concentrations. While the long-term significance of these episodes is unknown, most would agree that they should be avoided during treatment of hyperglycaemia with insulin. Emerging data further associate increased glycaemic variability with impaired long-term outcomes. Use of continuous (interstitial) glucose monitoring (CGM) in very preterm, VLBW infants has the potential to minimise the incidence and severity of hypoglycaemia and hyperglycaemia and increase glycaemic stability during critical developmental periods, providing new opportunities to improve long-term neurocognitive outcomes in these children by preventing these common but potentially harmful metabolic disorders. Thomson et al 1 report the results of a single-centre study in which feasibility of CGM for very preterm infants was assessed. The study was divided into two phases. In the first phase, accuracy was assessed by comparison of real-time (RT) CGM (Paradigm Veo, Medtronic MiniMed) to point-of-care (POC) blood glucose concentrations (Statstrip, Nova Biomedical) in 20 infants. In the second phase, a pilot study was conducted in which 20 infants were randomised to unblinded RT-CGM in conjunction with a clinical guideline dictating care decisions based on the CGM values versus standard neonatal care. In the standard care arm, infant interstitial glucose concentrations were measured with a blinded retrospective
PLOS ONE, 2015
Objectives Hypoglycemia is frequent in very low birth weight (VLBW) neonates and compromises their neurological outcome. The aim of this study was to compare real-time continuous glucose monitoring system (RT-CGMS) to standard methods by intermittent capillary blood glucose testing in detecting and managing hypoglycemia. Study design Forty-eight VLBW neonates were enrolled in this prospective study. During their 3 first days of life, their glucose level was monitored either by RT-CGMS (CGM-group), or by intermittent capillary glucose testing (IGM-group) associated with a blind-CGMS to detect retrospectively missed hypoglycemia. Outcomes were the number and duration of hypoglycemic (50mg/dl) episodes per patient detected by CGMS. Results Forty-three monitorings were analyzed (IGM n = 21, CGM n = 22), with a median recording time of 72 hours. In the IGM group, blind-CGMS revealed a significantly higher number of hypoglycemia episodes than capillary blood glucose testing (1.2AE0.4 vs 0.4AE0.2 episode/patient, p<0.01). In the CGM-group, the use of RT-CGMS made it possible (i) to detect the same number of hypoglycemia episodes as blind-CGMS (1.2AE0.4 episode/patient), (ii) to adapt the glucose supply in neonates with hypoglycemia (increased supply during days 1 and 2), and (iii) to significantly reduce the duration of hypoglycemia episodes per patient (CGM 44[10-140] min versus IGM 95[15-520] min, p<0.05). Furthermore, it reduced the number of blood samples (CGM 16.9AE1.0 vs IGM 21.9AE1.0 blood sample/patient, p<0.001).
Clinical Chemistry and Laboratory Medicine (CCLM), 2013
Background:The lack of accuracy of point of care (POC) glucose monitors has limited their use in the diagnosis of neonatal hypoglycemia. Hematocrit plays an important role in explaining discordant results. The objective of this study was to to assess the effect of hematocrit on the diagnostic performance of Abbott Precision Xceed Pro (PXP) and Nova StatStrip (StatStrip) monitors in neonates.Methods:All blood samples ordered for laboratory glucose measurement were analyzed using the PXP and StatStrip and compared with the laboratory analyzer (ABL 800 Blood Gas analyzer [ABL]). Acceptable error targets were ±15% for glucose monitoring and ±5% for diagnosis.Results:A total of 307 samples from 176 neonates were analyzed. Overall, 90% of StatStrip and 75% of PXP values met the 15% error limit and 45% of StatStrip and 32% of PXP values met the 5% error limit. At glucose concentrations ≤4 mmol/L, 83% of StatStrip and 79% of PXP values met the 15% error limit, while 37% of StatStrip and 38%...